open access

Vol 11, Supp. G (2015)
Case report
Published online: 2015-12-17
Get Citation

A long progression free survival time in a patient with metastatic neuroendocrine neoplasm of small intestine after treatment with long-acting octreotide and peptide receptor radionuclide therapy

Dorota Kaczmarska-Turek, Magdalena Pryć, Aneta Jańczyk, Bogna Ziarkiewicz-Wróblewska, Bartosz Cieślak, Krzysztof Woźniak, Tomasz Bednarczuk

open access

Vol 11, Supp. G (2015)
CASE REPORT
Published online: 2015-12-17

Abstract

Long-acting somatostatin analogs are considered as a first line of treatment in well-differentiated metastatic gastroenteropancreatic neuroendocrine neoplasms with symptoms of carcinoid syndrome, because of relief symptoms and antiproliferative effect. According to the results of PROMID study (Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors), median time to progression is 14.3 months during treatment with octreotide. In this case report we presented 46-year-old woman with primary diagnosis of hepatocellular carci­noma, treated with palliative chemiotherapy (doxorubicin, dexamethasone, cyclophosphamide) with hematologic side effects and after that in follow-up. Because of uncommon course of HCC, histopathology examination was reviewed. The new diagnosis was metastases of well-differentiated neuroendocrine tumor (G1 in WHO 2010 clas­sification). During diagnostic imaging (computed tomography of chest and abdomen, Gallium-68-DOTA-TATE PET/CT) primary tumor in small intestine was found. The final diagnosis was well-differentiated neuroendocrine neoplasm of small intestine with distant metastasis and carcinoid syndrome. Improvement of general condition and 26 months stabilization of the disease was observed after concomitant treatment with long-acting octreotide and peptide receptor radionuclide therapy.

Abstract

Long-acting somatostatin analogs are considered as a first line of treatment in well-differentiated metastatic gastroenteropancreatic neuroendocrine neoplasms with symptoms of carcinoid syndrome, because of relief symptoms and antiproliferative effect. According to the results of PROMID study (Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors), median time to progression is 14.3 months during treatment with octreotide. In this case report we presented 46-year-old woman with primary diagnosis of hepatocellular carci­noma, treated with palliative chemiotherapy (doxorubicin, dexamethasone, cyclophosphamide) with hematologic side effects and after that in follow-up. Because of uncommon course of HCC, histopathology examination was reviewed. The new diagnosis was metastases of well-differentiated neuroendocrine tumor (G1 in WHO 2010 clas­sification). During diagnostic imaging (computed tomography of chest and abdomen, Gallium-68-DOTA-TATE PET/CT) primary tumor in small intestine was found. The final diagnosis was well-differentiated neuroendocrine neoplasm of small intestine with distant metastasis and carcinoid syndrome. Improvement of general condition and 26 months stabilization of the disease was observed after concomitant treatment with long-acting octreotide and peptide receptor radionuclide therapy.

Get Citation

Keywords

carcinoid syndrome, neuroendocrine neoplasm, hepatocellular carcinoma, somatostatin analogs

About this article
Title

A long progression free survival time in a patient with metastatic neuroendocrine neoplasm of small intestine after treatment with long-acting octreotide and peptide receptor radionuclide therapy

Journal

Oncology in Clinical Practice

Issue

Vol 11, Supp. G (2015)

Article type

Case report

Pages

15-19

Published online

2015-12-17

Keywords

carcinoid syndrome
neuroendocrine neoplasm
hepatocellular carcinoma
somatostatin analogs

Authors

Dorota Kaczmarska-Turek
Magdalena Pryć
Aneta Jańczyk
Bogna Ziarkiewicz-Wróblewska
Bartosz Cieślak
Krzysztof Woźniak
Tomasz Bednarczuk

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl